Get a glimpse into our company and investor data—powered by the PitchBook Platform
Developer of pharmaceutical drugs created to focus on new non-psychotropic cannabinoids for the treatment of inflammatory and neurodegenerative diseases. The company's operations include development of cannabidiol and cannabigerol chemical derivatives that improve the therapeutic properties of the natural hit compounds which addresses unmet clinical need in the treatment of multiple sclerosis, Huntington's disease and scleroderma.
Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
---|
This information is reserved for PitchBook Platform users. To explore Emerald Health Biotechnology‘s full profile, request access.
Request full access to PitchBook